BX · News · 20261106N
VITALYST Heart Pump Development
Blackstone Inc. · 2026-11-06 · Importance 34 · Surprise 42 · In source text
Blackstone Life Sciences and Boston Scientific agreed to co-fund development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System through a $455 million collaboration. The miniature heart pump is designed to treat acute myocardial infarction cardiogenic shock by increasing cardiac output and improving blood flow to vital organs. The collaboration targets improvements in the efficacy, safety, and ease of use of mechanical circulatory support technologies for critically ill patients.
Key facts
- Blackstone Life Sciences and Boston Scientific are co-funding development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System through a $455 million collaboration. source
- Blackstone Life Sciences entered a $455 million co-funding agreement with Boston Scientific for its VITALYST heart pump. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | — | Blackstone Life Sciences entered a $455 million co-funding agreement with Boston Scientific for its VITALYST heart pump. |